Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Yurika Nakagawa"'
Autor:
Yuta Mitobe, Shuhei Suzuki, Kazuki Nakamura, Yurika Nakagawa-Saito, Senri Takenouchi, Keita Togashi, Asuka Sugai, Yukihiko Sonoda, Chifumi Kitanaka, Masashi Okada
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 17, p 9473 (2024)
Radiation therapy continues to be the cornerstone treatment for malignant brain tumors, the majority of which express wild-type p53. Therefore, the identification of drugs that promote the ionizing radiation (IR)-induced activation of p53 is expected
Externí odkaz:
https://doaj.org/article/e70c67fdecb240c5a8071053fc498f92
Autor:
Yurika Nakagawa-Saito, Yuta Mitobe, Keita Togashi, Shuhei Suzuki, Asuka Sugai, Senri Takenouchi, Kazuki Nakamura, Yukihiko Sonoda, Chifumi Kitanaka, Masashi Okada
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 7, p 3948 (2024)
The prevention of tumor recurrence by the successful targeting of glioma stem cells endowed with a tumor-initiating capacity is deemed the key to the long-term survival of glioblastoma patients. Glioma stem cells are characterized by their marked the
Externí odkaz:
https://doaj.org/article/526f5d81dc344162af5e532e72375290
Autor:
Yuta Mitobe, Shuhei Suzuki, Yurika Nakagawa-Saito, Keita Togashi, Asuka Sugai, Yukihiko Sonoda, Chifumi Kitanaka, Masashi Okada
Publikováno v:
Biomedicines, Vol 11, Iss 7, p 1967 (2023)
A significant proportion of meningiomas are clinically aggressive, but there is currently no effective chemotherapy for meningiomas. An increasing number of studies have been conducted to develop targeted therapies, yet none have focused on the p53 p
Externí odkaz:
https://doaj.org/article/6bc8b58de44d43a88c06ccbee45a0e26
Autor:
Yurika Nakagawa-Saito, Yuta Mitobe, Shuhei Suzuki, Keita Togashi, Asuka Sugai, Chifumi Kitanaka, Masashi Okada
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 13, p 10817 (2023)
The deregulation of the FOXM1 transcription factor is a key molecular alteration in ovarian cancer, contributing to the development and progression of ovarian cancer via activation of the target genes. As such, FOXM1 is a highly attractive therapeuti
Externí odkaz:
https://doaj.org/article/24202894c3024d11bd57e4eb8946315d
Autor:
Masashi Okada, Yurika Nakagawa-Saito, Yuta Mitobe, Asuka Sugai, Keita Togashi, Shuhei Suzuki, Chifumi Kitanaka
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 15, p 8785 (2022)
Glioma stem cells (GSCs), the cancer stem cells of glioblastoma multiforme (GBM), contribute to the malignancy of GBM due to their resistance to therapy and tumorigenic potential; therefore, the development of GSC-targeted therapies is urgently neede
Externí odkaz:
https://doaj.org/article/9581583e40cd40a19767bed45450dfd2
Autor:
Yurika Nakagawa-Saito, Shinichi Saitoh, Yuta Mitobe, Asuka Sugai, Keita Togashi, Shuhei Suzuki, Chifumi Kitanaka, Masashi Okada
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 15, p 8084 (2022)
Cancer stem cells (CSCs) are in general characterized by higher resistance to cell death and cancer therapies than non-stem differentiated cancer cells. However, we and others have recently revealed using glioma stem cells (GSCs) as a model that, une
Externí odkaz:
https://doaj.org/article/7adcb5e9d86d4459b0db0fd5beb8aa84
Autor:
YURIKA NAKAGAWA-SAITO, YUTA MITOBE, KEITA TOGASHI, SHUHEI SUZUKI, ASUKA SUGAI, CHIFUMI KITANAKA, MASASHI OKADA
Publikováno v:
Anticancer Research. 43:1131-1138
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::255746ca91c90a09db060a473fc1dd5b
https://doi.org/10.21873/anticanres.16258
https://doi.org/10.21873/anticanres.16258
Autor:
Okada, Yurika Nakagawa-Saito, Yuta Mitobe, Shuhei Suzuki, Keita Togashi, Asuka Sugai, Chifumi Kitanaka, Masashi
Publikováno v:
International Journal of Molecular Sciences; Volume 24; Issue 13; Pages: 10817
The deregulation of the FOXM1 transcription factor is a key molecular alteration in ovarian cancer, contributing to the development and progression of ovarian cancer via activation of the target genes. As such, FOXM1 is a highly attractive therapeuti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::3d8c798245924127002bae875caccf76
Autor:
Kazuko Omodaka, Kota Sato, Toru Nakazawa, Hiroyuki Asada, Yurika Nakagawa, Masaki Kenji, Shinobu Fujii
To investigated whether a new drug delivery system (DDS) could enable the controlled release of tafluprost and suppress retinal ganglion cell (RGC) death in rats after optic nerve transection (ONT). A DDS containing 0.04%, 0.20% or 1.00% tafluprost,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd8339c7dbb32c6727dddea23026988a
Autor:
Taiki Kokubun, Seizo Koshiba, Akira Uruno, Ritsumi Saito, Amane Fujioka, Yukihiro Shiga, Ikuko N. Motoike, Masayuki Yamamoto, Toru Nakazawa, Koji M. Nishiguchi, Kazuko Omodaka, Kazuichi Maruyama, Daisuke Saigusa, Kota Sato, Yurika Nakagawa
Publikováno v:
Scientific Reports, Vol 8, Iss 1, Pp 1-13 (2018)
Scientific Reports
Scientific Reports
In glaucoma, although axonal injury drives retinal ganglion cell (RGC) death, little is known about the underlying pathomechanisms. To provide new mechanistic insights and identify new biomarkers, we combined latest non-targeting metabolomics analyse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b18c039761a004f21c5a4dd3bf52a17
http://link.springer.com/article/10.1038/s41598-018-30464-z
http://link.springer.com/article/10.1038/s41598-018-30464-z